Assyro AI

FDA Orange Book · active-ingredient family

Cenobamate

Cenobamate is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.

Reference-listed drug:XCOPRI · NDA 212839

1

Brand (NDA)

0

Generics (ANDA)

2

Listed patents

0

Exclusivity periods

Brand (NDA) products · tablet

ProductApplicantApplicationTEApproved
XCOPRIRLD×6SK LIFENDA 212839—Mar 10, 2020

Listed patents (2)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
7598279Oct 30, 2032in 6 yr 6 mo
Substance
11654133Jun 16, 2039in 13 yr 2 mo
U-3610

Cenobamate — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo